icodextrin and Nephrotic-Syndrome

icodextrin has been researched along with Nephrotic-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for icodextrin and Nephrotic-Syndrome

ArticleYear
Eosinophilia in a peritoneal dialysis patient: Answers.
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:9

    Icodextrin is a starch-derived glucose polymer used in peritoneal dialysis dialysate to treat volume overload by increasing ultrafiltration in patients with end-stage renal disease. Reported adverse reactions to icodextrin are mild and rare and mainly consist of skin rash that resolves spontaneously after discontinuation of treatment. We describe a young patient with extreme eosinophilia that appeared with the use of icodextrin, disappeared after its discontinuation, and reappeared after a rechallenge with the drug. The eosinophilia was not associated with peritonitis, was asymptomatic, and fully resolved after discontinuation of the drug. Severe eosinophilia can potentially cause tissue damage in several organs, which would indicate that blood eosinophil count is recommended in routine complete blood counts while icodextrin peritoneal dialysis is being administered.

    Topics: Ascitic Fluid; Asymptomatic Diseases; Child, Preschool; Diagnosis, Differential; Dialysis Solutions; Eosinophilia; Humans; Icodextrin; Kidney Failure, Chronic; Male; Nephrotic Syndrome; Peritoneal Dialysis; Peritonitis

2018
A patient with refractory nephrotic syndrome withdrawn from peritoneal dialysis.
    Clinical and experimental nephrology, 2010, Volume: 14, Issue:4

    A 67-year-old woman was admitted to our hospital because of anasarca due to refractory nephrotic syndrome and chronic renal insufficiency. Laboratory data indicated serum total protein of 4.8 g/dl, albumin of 1.5 g/dl, creatinine of 1.9 mg/dl and BUN of 17 mg/dl. Urinary protein excretion was 7.8 g/day. Because of severe atrophy of both kidneys, neither renal biopsy nor immunosuppressive treatment was performed. Since conservative management including bed rest, diet therapy, limitation of water intake and administration of diuretics was not effective, peritoneal dialysis therapy using icodextrin only at night was started. The amount of water removal was steadily secured without progressing renal dysfunction or decreasing urine volume. From day 290 onward, the urinary protein excretion was decreased to show complete remission and urine volume increased. On day 528, peritoneal dialysis was discontinued, and thereafter only peritoneal lavage was performed. On day 858, the catheter was removed from the abdominal cavity, and thereafter diuretics could be discontinued. The reason for the dramatic reduction of urinary protein in this patient is unclear. However, it is possible that the primary disease such as membranous nephritis showed remission while the patient was undergoing icodextrin peritoneal dialysis, which preserves renal function but not extracorporeal ultrafiltration or hemodialysis. Icodextrin peritoneal dialysis may be an alternative to hemodialysis for refractory fluid overload in patients with nephrotic syndrome and may have the advantage of preserving renal function.

    Topics: Aged; Atrophy; Diuretics; Drug Administration Schedule; Female; Glucans; Glucose; Hemodialysis Solutions; Humans; Icodextrin; Kidney; Nephrotic Syndrome; Peritoneal Dialysis; Peritoneal Lavage; Proteinuria; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome

2010